Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors

A novel class of imidazopyridine derivatives was designed as PLK1 inhibitors. Extensive SAR studies supported by molecular modeling afforded a highly potent and selective compound 36. Compound 36 demonstrated good antitumor efficacy in xenograft nude rat model.

Design and optimization of novel imidazopyridine derivatives led to the identification of a potent and selective PLK inhibitor 36.Figure optionsDownload as PowerPoint slide